Key result
Dual blockade of the renin-angiotensin-aldosterone system using ACE inhibitors and ARBs is not supported by current evidence, though other combinations remain under investigation.
Why the study?
Does dual blockade of the renin-angiotensin-aldosterone system provide advantages in patients with arterial hypertension and diabetes?
Does dual blockade of the renin-angiotensin-aldosterone system provide advantages in patients with arterial hypertension and diabetes?
This review highlights that while ACEi/ARB dual blockade is not supported by current evidence, other dual RAAS blockade strategies remain under investigation for hypertension and diabetes.
Answers are grounded in this paper and cite their sources.
ACEi/ARB dual blockade lacks support in hypertension with diabetes; leaves open other RAAS combinations for prospective trials.
Antagonism of renin-angiotensin-aldosterone system is exerted through angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, renin inhibitors and mineralocorticoid receptor antagonists. These drugs have been successfully tested in numerous trials and in different clinical settings. The original indications of renin-angiotensin-aldosterone system blockers have progressively expanded from the advanced stages to the earlier stages of cardiorenal continuum. To optimize the degree of blockade of renin-angiotensin-aldosterone system, dose uptitrations of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists or the use of a dual blockade, initially identified with the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists, have been proposed. The data from the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study do not support this specific dual blockade approach. However, the dual blockade of angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists with direct renin inhibitors is currently under investigation while that based on an aldosterone blocker with any of the previous three drugs requires more evidence beyond heart failure. In this review, we revisited potential advantages of dual blockade of renin-angiotensin-aldosterone system in arterial hypertension and diabetes.
No takes yet. Share an insight, caveat, or question.
Volpe et al. (2012) conducted a review in Arterial hypertension and diabetes. Dual blockade of the renin-angiotensin-aldosterone system was evaluated. Dual blockade of the renin-angiotensin-aldosterone system using ACE inhibitors and ARBs is not supported by current evidence, though other combinations remain under investigation.
Synapse has enriched 10 related papers. Consider them for comparative context: